Aduro Biotech Inc. (ADRO) CEO Stephen T. Isaacs Sells 27,273 Shares of Stock
Aduro Biotech Inc. (NASDAQ:ADRO) CEO Stephen T. Isaacs sold 27,273 shares of the firm’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $12.67, for a total value of $345,548.91. Following the sale, the chief executive officer now directly owns 129,473 shares in the company, valued at approximately $1,640,422.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Aduro Biotech Inc. (NASDAQ:ADRO) opened at 13.64 on Thursday. The company’s market capitalization is $883.24 million. The stock has a 50 day moving average price of $14.13 and a 200 day moving average price of $13.11. Aduro Biotech Inc. has a 52-week low of $7.26 and a 52-week high of $34.95.
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.21. Aduro Biotech had a negative net margin of 23.69% and a negative return on equity of 9.23%. The business earned $39 million during the quarter, compared to analyst estimates of $25.24 million. Aduro Biotech’s revenue was up 306.3% on a year-over-year basis. Equities research analysts forecast that Aduro Biotech Inc. will post ($1.39) earnings per share for the current year.
ADRO has been the topic of several recent research reports. Roth Capital reissued a “buy” rating and set a $22.00 price objective on shares of Aduro Biotech in a report on Monday, July 11th. Zacks Investment Research downgraded Aduro Biotech from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 target price on shares of Aduro Biotech in a research report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $22.00.
Several institutional investors have recently modified their holdings of the stock. Sphera Funds Management LTD. increased its position in shares of Aduro Biotech by 41.7% in the first quarter. Sphera Funds Management LTD. now owns 170,000 shares of the company’s stock valued at $2,178,000 after buying an additional 50,000 shares during the period. American Century Companies Inc. purchased a new position in shares of Aduro Biotech during the second quarter valued at approximately $1,265,000. State Street Corp increased its position in shares of Aduro Biotech by 33.0% in the first quarter. State Street Corp now owns 160,860 shares of the company’s stock valued at $2,062,000 after buying an additional 39,952 shares during the period. Alps Advisors Inc. increased its position in shares of Aduro Biotech by 27.7% in the second quarter. Alps Advisors Inc. now owns 90,766 shares of the company’s stock valued at $1,027,000 after buying an additional 19,663 shares during the period. Finally, Franklin Resources Inc. increased its position in shares of Aduro Biotech by 0.6% in the first quarter. Franklin Resources Inc. now owns 893,210 shares of the company’s stock valued at $11,442,000 after buying an additional 5,527 shares during the period. 29.76% of the stock is owned by hedge funds and other institutional investors.
About Aduro Biotech
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.